Eli Lilly shares rise on 2026 forecast
Eli Lilly's stock soared by up to 7% after raising its revenue forecast for 2026 to between $85 billion and $87 billion, up from the previous estimate of $85 billion. This positive outlook was supported by strong demand for the company's products, especially GLP-1 medications like the weight-loss drug Fondayo, which received FDA approval. Additionally, the company completed clinical trials for the drug Retatrutide and plans to submit a regulatory application in the first quarter of next year as part of its efforts to strengthen its position in the weight-loss and healthcare markets. The company's shares have increased by more than 40% since the end of April, with ongoing attention on how its innovations can support revenue streams and meet the growing global demand.
Notice: This Is an AI-Generated Summary
Comments (0)